Results 51 to 60 of about 18,120 (266)

A case of infant botulism in a 4-month-old baby [PDF]

, 2016
This case-report highlights: i) the difficulty of IB diagnosis as it is a rare syndrome with subclinical onset, ii) the need for an accurate training for physicians involved in IB management, iii) the efficacy and safety of TEqA in IB treatment, iv ...
Bruna Auricchio, Dilettta Sabatini, Fabrizio Anniballi, GRASSI, Maria Caterina, Laura Papetti, LONATI, DAVIDE, PROPERZI, Enrico   +6 more
core   +1 more source

Histological and immunohistochemical findings of the action of botulinum toxin in salivary gland: systematic review

Brazilian Journal of Biology
The treatment of sialorrhea is necessary for the constant risks posed by hypersalivation. A new therapeutic option comes up with the application of botulinum toxin in salivary glands.
J. B. Oliveira, J. Evêncio-Neto, L. Baratella-Evêncio   +2 more
doaj   +1 more source

Measuring Effects on Pain and Quality of Life after Abobotulinum Toxin A Injections in Children with Cerebral Palsy

Toxins, 2022
Sixty-seven percent of children with cerebral palsy (CCP) experience pain. Pain is closely interrelated to diminished quality of life. Despite this, pain is an overlooked and undertreated clinical problem.
Christian Wong, Ian Westphall, Josephine Sandahl Michelsen   +2 more
doaj   +1 more source

Gastrointestinal Manifestations in Rubinstein‐Taybi Syndrome

American Journal of Medical Genetics Part A, EarlyView.
ABSTRACT Rubinstein–Taybi syndrome is a rare genetic condition associated with a wide range of physical, cognitive, and developmental impairments, yet its gastrointestinal manifestations remain poorly characterized. Case reports and small series suggest a high prevalence of gastroesophageal reflux, constipation, dysphagia, and nutritional compromise ...
Mohamad Abi Nassif, Ajay Kaul, Lev Dorfman, Khalil El‐Chammas   +3 more
wiley   +1 more source

Producing positive control materials for template in PCR testing to detect botulinum neurotoxin types A and B genes

Tạp chí Kiểm nghiệm và An toàn thực phẩm
Botulinum neurotoxin (BoNT) is produced by the bacterium Clostridium botulinum and some other bacterial strains such as C. butyricum and C. baratii. It is considered the strongest toxin known to humans and can cause botulism.
Ninh Thi Hanh, Le Vinh Hoa, Tran Hong Ba, Pham Van Quan, Le Thanh Long, Pham Thi Loan   +5 more
doaj   +1 more source

Botulinum toxin type A on cutaneous flap viability in diabetic and tobacco-exposed rats [PDF]

Acta Cirúrgica Brasileira, 2015
PURPOSE:To investigate the effect of Botulinum toxin A (BoNTA) on skin flap viability in healthy, tobacco-exposed and diabetic rats.METHODS: Ninety male Wistar rats (250-300g) were randomly divided into six groups: control+saline (C1), control+BoNTA (C2),
Cristina Pires Camargo, Alfredo Luiz Jacomo, Cláudia Naves Battlehner, Miriam Lemos, Paulo Hilário Saldiva, Milton Arruda Martins, Alexandre Mendonça Munhoz, Rolf Gemperli   +7 more
doaj   +1 more source

Intravesical Injection of Botulinum Toxin Type A in Patients with Refractory Overactive Bladder—Results between Young and Elderly Populations, and Factors Associated with Unfavorable Outcomes

Toxins, 2023
Intravesical botulinum toxin type A (BoNT-A) injection has been recognized as the standard treatment for refractory overactive bladder (OAB). However, its therapeutic efficacy and safety have not been thoroughly reviewed in elderly patients.
Yin-Chien Ou, Yao-Lin Kao, Yi-Hui Ho, Kuan-Yu Wu, Hann-Chorng Kuo   +4 more
doaj   +1 more source

Cost-Effectiveness of Treating Upper Limb Spasticity Due to Stroke with Botulinum Toxin Type A: Results from the Botulinum Toxin for the Upper Limb after Stroke (BoTULS) Trial [PDF]

, 2012
Stroke imposes significant burdens on health services and society, and as such there is a growing need to assess the cost-effectiveness of stroke treatment to ensure maximum benefit is derived from limited resources.
Christopher Price, Curtis, Frederike Wijck, Garces, Gary Ford, Helen Rodgers, Laura Graham, Lisa Shaw, Michael Barnes, Nick Steen, O’Brien, Phil Shackley, Saka, Schafer, Shaw, Ward, Youman   +16 more
core   +3 more sources

The 9th International RASopathies Symposium

American Journal of Medical Genetics Part A, EarlyView.
ABSTRACT The RASopathies are a group of congenital disorders with overlapping clinical manifestations that are caused by pathogenic germline or early somatic variants that result in the hyperactivation of the RAS/mitogen‐activated protein kinase (MAPK) signaling pathway.
Pau Castel, Lisa Schoyer, Beth Stronach, Raya Bogdanova, Anton M. Bennett, Jaishri Blakeley, Miriam Bornhorst, Tammy Bowers, Saskia M. Brachmann, Emma Burkitt‐Wright, Kathryn Chatfield, Alessandro De Luca, Khalil El‐Chammas, Abdul Elkadri, John E. Fortunato, Bruce D. Gelb, Anne Goriely, Karen Gripp, Kassidy Grover, Lindsay Homan, Kenneth A. Kern, Maija Kiuru, Charles (Chuck) Lawson, Yong‐Seok Lee, Frank McCormick, Gina Ney, Cristina Nuevo‐Tapioles, Sara Pardej, Elizabeth I. Pierpont, Julia Plank, Nancy Ratner, Katherine A. Rauen, J. Elliott Robinson, Les Rogers, Sarah E. Sheppard, Keir Shiels, David Stevenson, Dagmar Tiemens, Matthew Traylor, K. Nicole Weaver, Marielle Yohe, Tamar Green   +41 more
wiley   +1 more source

Pathways for Diagnosis and Multimodal Management, Including Botulinum Neurotoxin Therapy, in Shoulder Conditions Following Acquired Central Nervous System Lesions

Toxins
There is limited published guidance available to help less experienced practitioners assess and manage shoulder conditions, including spasticity, after acquired central nervous system (CNS) lesions. To address this gap, 11 spasticity and dystonia experts
Bo Biering-Sørensen, Carlos Cordero-García, Chris Boulias, Damon Hoad, Djamel Bensmail, Franco Molteni, François Genêt, Jörg Wissel, Jorge Jacinto, Philippe Marque, Steffen Berweck   +10 more
doaj   +1 more source